SCHEMBL4090084

SCHEMBL4090084

Cc1sc(NC(=O)C2C(C)(C)C2(C)C)c(C(=O)NC2CCCC2)c1C

nearest known ligand 0.47

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.47
MAPT P10636 4/20 0.47
KDM4E B2RXH2 2/20 0.47
HPGD P15428 2/20 0.47
TAS1R3 Q7RTX0 6/20 0.46
TAS1R1 Q7RTX1 5/20 0.46
TAS1R2 Q8TE23 5/20 0.46
L3MBTL1 Q9Y468 1/20 0.44
RAB9A P51151 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.43
RXFP1 Q9HBX9 1/20 0.43
LMNA P02545 1/20 0.43
ABCC1 P33527 1/20 0.41
POLB P06746 1/20 0.40
EGLN1 Q9GZT9 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4089512 0.99 TAS1R3 (0.47) ALDH1A1MAPTKDM4EHPGDTAS1R3
SCHEMBL4091305 0.97 ALDH1A1 (0.47) ALDH1A1MAPTKDM4EHPGDTAS1R3
SCHEMBL4084014 0.95 ALDH1A1 (0.46) ALDH1A1MAPTKDM4EHPGDTAS1R3
SCHEMBL4080979 0.80 ALDH1A1 (0.60) ALDH1A1MAPTKDM4EHPGDL3MBTL1
SCHEMBL4084751 0.78 CNR2 (0.58) ALDH1A1MAPTKDM4EHPGDABCC1
SCHEMBL3745498 0.78 ABCC1 (0.51) ALDH1A1MAPTKDM4EHPGDL3MBTL1
SCHEMBL4080989 0.77 CNR2 (0.46) ALDH1A1MAPTKDM4EHPGDLMNA
SCHEMBL4091316 0.76 ALDH1A1 (0.58) ALDH1A1MAPTKDM4EHPGDL3MBTL1
SCHEMBL4085526 0.76 CNR2 (0.47) ALDH1A1MAPTKDM4EHPGDPOLB
SCHEMBL4091302 0.75 ALDH1A1 (0.48) ALDH1A1MAPTKDM4EHPGDTAS1R3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8338623-B2 N-{3-[(2,5-dimethylmorpholin-4-yl)carbonyl]-4,7-dihydro-5H-thieno[2,3-c]pyran-2-yl}hexahydro-2,5-methanopentalene-3a(1H)-carboxamide; CB2 receptors ligand; antiinflammatory, analgesic agent; autoimmune diseases; neuroprotectants ABBVIE INC. (US) 2012-12-25 US disclosed
US-20090018114-A1 NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS ABBOTT LABORATORIES (US) 2009-01-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090018114-A1 NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS CNR1, CNR2, GPR18 ALDH1A1 1504/4885MAPT 2527/4885KDM4E 2443/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.